ISRCTN ISRCTN82038982
DOI https://doi.org/10.1186/ISRCTN82038982
IRAS number 1008652
Secondary identifying numbers RXC008-0001, IRAS 1008652
Submission date
04/03/2024
Registration date
04/03/2024
Last edited
04/03/2024
Recruitment status
No longer recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Study website

Contact information

Dr Helen Timmis
Public, Scientific

Redx Pharma Plc
Block 33
Mereside
Alderley Park
Cheshire
SK10 4TG
United Kingdom

Phone +44 (0)7854 608 784
Email h.timmis@redxpharma.com
Dr Annelize Koch
Principal Investigator

Simbec-Orion Clinical Pharmacology
Merthyr Tydfil Industrial Park
Cardiff Road
Merthyr Tydfil
CF48 4DR
United Kingdom

Phone +44 (0)1443 694313
Email annelize.koch@simbecorion.com

Study information

Study designA three-part first-in-human trial in up to 104 healthy participants and patients with strictures due to Crohn’s Disease
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Pharmaceutical testing facility
Study typeOther, Safety
Participant information sheet Not available in web format
Scientific titlePhase I Trial: RD 783.35406 (RXC008-0001)
Study acronymNil known
Study hypothesisThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Ethics approval(s)

1. Approved 20/12/2023, Wales Research Ethics Committee 2 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941119; Wales.REC2@wales.nhs.uk), ref: 23.WA.0280

2. Approved 27/12/2023, MHRA (MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 48121/0006/001-0001

ConditionHealthy volunteers and patients with strictures due to Crohn’s Disease
InterventionThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Intervention typeDrug
Pharmaceutical study type(s)Pharmacokinetic, Pharmacodynamic
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Primary outcome measureThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Secondary outcome measuresThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Overall study start date27/09/2023
Overall study end date05/09/2024

Eligibility

Participant type(s)Healthy volunteer, Patient
Age groupAdult
Lower age limit18 Years
Upper age limit50 Years
SexMale
Target number of participants104
Participant inclusion criteriaThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Participant exclusion criteriaThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Recruitment start date25/01/2024
Recruitment end date07/08/2024

Locations

Countries of recruitment

  • United Kingdom
  • Wales

Study participating centre

Simbec Research Limited
Simbec House Merthyr Tydfil Industrial Park
Merthyr Tydfil Industrial Park
Pentrebach 
Merthyr Tydfil
Mid Glamorgan 
CF48 4DR
United Kingdom

Sponsor information

Redx Pharma (United Kingdom)
Industry

Redx Pharma Plc (United Kingdom)
Block 33
Mereside
Alderley Park
Cheshire
SK10 4TG
England
United Kingdom

Phone N/A
Email info@redxpharma.com
Website https://www.redxpharma.com/
ROR logo "ROR" https://ror.org/04wysdg63

Funders

Funder type

Industry

Redx Pharma Plc

No information available

Results and Publications

Intention to publish date31/12/2025
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planFull trial details will be published up to 30 months after the end of the trial. Publication of some trial details is deferred because of the high commercial sensitivity of this Phase I study and the negligible benefit to the public of phase I information. Results will be posted on or after the date of publication of full trial details.
IPD sharing planThe datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

Editorial Notes

04/03/2024: Study's existence confirmed by Wales Research Ethics Committee 2.